Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy

Autor: Mario Perro, Vaios Karanikas, Marcin Kowanetz, Andreas Roller, Christian Klein, Marieke F. Fransen, Ines Matos, Stefano Sammicheli, Stanford Chen, Eva Sum, Pablo Umana, Vesna Pulko, Christian Jost, Regula B. Buser, Daniel S. Chen, Priti S. Hegde, Ferry Ossendorp, Sara Colombetti, Maud Léa Mayoux, Wei Xu, Anton Belousov, Karolin Rommel

Publikováno v: Mayoux, M, Roller, A, Pulko, V, Sammicheli, S, Chen, S, Sum, E, Jost, C, Fransen, M F, Buser, R B, Kowanetz, M, Rommel, K, Matos, I, Colombetti, S, Belousov, A, Karanikas, V, Ossendorp, F, Hegde, P S, Chen, D S, Umana, P, Perro, M, Klein, C & Xu, W 2020, ' Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy ', Science Translational Medicine, vol. 12, no. 534, eaav7431 . https://doi.org/10.1126/scitranslmed.aav7431
Science Translational Medicine, 12(534):eaav7431. American Association for the Advancement of Science
Science Translational Medicine, 12(534). AMER ASSOC ADVANCEMENT SCIENCE

PD-L1/PD-1 blocking antibodies have demonstrated therapeutic efficacy across a range of human cancers. Extending this benefit to a greater number of patients, however, will require a better understanding of how these therapies instigate anticancer im

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39640977c6c4ccd751747fb8e0e597a6
http://www.scopus.com/inward/record.url?scp=85081938059&partnerID=8YFLogxK

Abstract 1594: Enhancement of the anti-tumor activity of CEA TCB via combination with checkpoint blockade by PD-L1 and interleukin-2 variant immunocytokine

Autor: Nicolini Valeria G, Inja Waldhauer, Linda Fahrni, Tanja Fauti, Johannes Sam, Marina Bacac, Karolin Rommel, Marine Le Clech, Christian Gerdes, Pablo Umana, Xavier Miot, Petros Papastogiannidis, Sara Colombetti, Christian Klein

Publikováno v: Cancer Research. 77:1594-1594

Cancer immunotherapy represents a promising therapeutic approach to extend the overall survival of cancer patients. However, several mechanisms within the tumor microenvironment orchestrate the suppression of host immune response requiring combinatio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::467fbdb919fe55632131088a0b5af7fb
https://doi.org/10.1158/1538-7445.am2017-1594

STAT6-mediated BCL6 repression in primary mediastinal B-cell lymphoma (PMBL)

Autor: Ralf Marienfeld, Olga Ritz, Karolin Rommel, Karola Dorsch, Vasiliki Papadopoulou, Elena Kelsch, Jochen K. Lennerz, Simon D. Wagner, Michaela Buck, Karen Leroy, Julia Melzner, Silke Brüderlein, Peter Møller

Publikováno v: Europe PubMed Central
ResearcherID
Oncotarget

Primary mediastinal B-cell lymphoma (PMBL) is characterized by aberrant activation of JAK/STAT-signaling resulting in constitutive presence of phosphorylated STAT6 (pSTAT6). In primary PMBL samples pSTAT6 is only expressed in a sub-population of lymp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92dd7821f7535cb3840f26a32a215043
http://europepmc.org/abstract/med/23852366